Interim analysis of a phase II trial of cyclophosphamide, epirubicin and 5-fluorouracil (CEF) followed by docetaxel as preoperative chemotherapy for early stage Breast carcinoma

Breast Cancer

Volumn 12, Issue 2, 2005, Pages 99-103

  Iwata, Hiroji ^a,b   Nakamura, Seigo ^b   Toi, Masakazu ^b   Shin, Eisei ^b   Masuda, Norikazu ^b   Ohno, Shinji ^b   Takatsuka, Yuichi ^b   Hisamatsu, Kazufumi ^b   Yamazaki, Kosuke ^b   Kusama, Mikihiro ^b   Kaise, Hiroshi ^b   Sato, Yasuyuki ^b   Kuroi, Katsumasa ^b   Akiyama, Futoshi ^b   Tsuda, Hitoshi ^b   Kurosumi, Masafumi ^b  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

^b Japan Breast Cancer Research Group (JBCRG)   (Japan)

Author keywords

CEF; Docetaxel; Preoperative chemotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; TAXOID;

ADJUVANT THERAPY; ADULT; ARTICLE; BREAST TUMOR; CARCINOMA; CLINICAL TRIAL; DOSE RESPONSE; DRUG ADMINISTRATION; FEMALE; HUMAN; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PHASE 2 CLINICAL TRIAL; SEGMENTAL MASTECTOMY; STATISTICS; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EPIRUBICIN; FEMALE; FLUOROURACIL; HUMANS; MASTECTOMY, SEGMENTAL; MIDDLE AGED; NEOADJUVANT THERAPY; TAXOIDS; TREATMENT OUTCOME;

EID: 24344501324     PISSN: 13406868     EISSN: 18804233     Source Type: Journal    
DOI: 10.2325/jbcs.12.99     Document Type: Conference Paper

References (14)

1. Fisher B, Bryant J, Wolmark N, Mamounas E, Brown Ann, Fisher ER, Wicerham DL, Begovic M, De Cillis A, Robidoux A, Margolese RG, Cruz AB, Hoen JL, Lees AW, Dimitrov NV, Bear HD: Effect of prospective chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16:2672-2685, 1998. (Pubitemid 28363030)
2. Van der Huge JA, Van der Velde C J H, Julien JP, Tubiana-Hulin M, Vandervelden C, Duchateau L; Cooperating investigators: Preoperative chemotherapy in primary operable breast cancer: results from the European organization for research and treatment of cancer trial 10902. J Clin Oncol 19:4224-4237, 2001. (Pubitemid 33081640)
3. Kuerer HM, Newman LA, Smith TL, Ames FC, Hunt KK, Dhingra K, Theriault RL, Singh G, Binkley SM, Sneige N, Buchhols TA, Ross MI, McNeese MD, Buzdar AU, Hortobagyi GN, Eva Singletary S: Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorabicine-based neoadjuvant chemotherapy. J Clin Oncol 17:460-469, 1999. (Pubitemid 29075229)
4. Scholl SM, Fourqeet A, Asselain B, Pierga JY, Vilcoq JR, Durand JC, Dorval T, Palangie T, Louve M, Beuzeboc P: Neoadjuvant versus adjuvant chemotherapy in premonopausal patients with tumours considered too large for breast conserving surgery preliminary results of a randomized trial: S6. Eur J Cancer 30:645-652, 1994. (Pubitemid 24164252)
5. Mauriac L, MacGrogan G, Avril A, Durand M, Floquet A, Deblet M, Dihuydy JM, Bonichon F: Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow up. Institut Bergoni Bordeaux Groupe Sein (IBBGS). Ann Oncol 10:47-52, 1999. (Pubitemid 29090591)
6. Von Minckwitz G, Costa SD, Raab G, Blohmer LU, Eidtmann H, Hilfrich L, Merkle E, Jackisch C, Gademann G, Tulusan AH, Eiermann W, Graf E, Kaufman M: Dose-dense doxorubicin, docetaxel, and granulocyte colony-stimilating factor support with or without tamoxifen as preoperative therapy in patients with operable carcinoma of the breast: a randomized, controlled, open phase IIb study. J Clin Oncol 17:460-469, 1999.
7. Adachi I, Watanabe T, Takashima S, Narabayashi M, Horikoshi N, Aoyama H, Taguchi T: A late phase II study of RP56976 (docetaxel) in patients with advanced or recurrent cancer. British J Cancer 73:210-216, 1996. (Pubitemid 26028336)
8. Heys SD, Hutcheon AW, Sarkar TK, Ogston KN, Miller ID, Payne S, Smith I, Walker LG, Eremin O; Aberdeen Breast Group: Neoadjuvant docetaxel in breast cancer: 3-year survival results from the Aberdeen trial. Clin Breast Cancer 2:S69-74, 2002. (Pubitemid 35423140)
9. Bear HD, Anderson S, Brown A, Smith R, Mamounas EP, Fisher B, Margolese R, Theoret H, Soran A, Wickerham DL, Wolmark N; National Surgical Adjuvant Breast and Bowel Project B-27: The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 21:4165-4174, 2003. (Pubitemid 46606185)
10. Commitee for Production of Histopathological Criteria, Japanese Breast Cancer Society, Chairman: Kurosumi M, Members: Akiyama F, Iwase T, Motomura K, Okazaki M, and Tsuda H: Histopathological Criteria for Assessment of Therapeutic Response in Breast Cancer. Breast Cancer 8:1-2, 2001.
11. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Glabbeke MV, Oosterom AT, Christian NC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205-216, 2000. (Pubitemid 30099779)
12. Gradishar WJ: Docetaxel as neoadjuvant chemotherapy in patients with stage III breast cancer. Oncology 11(suppl 8):15-18, 1997. (Pubitemid 27357871)
13. Amat S, Bougnoux P, Penault-Llorca F, Fetissof F, Cure H, Kwiatkowski F, Achard J-L, Body G, Dauplat J, Chollet P: Neoadjuvant docetaxel for operable breast cancer induces a hig pathological response and breast-cobservation rate. British J Cancer 88:1339-1345, 2003. (Pubitemid 36606412)
14. Piccart MJ, Klijin J, Paridaens R, Nooij M, Mauriac L, Coleman R, Bontenbal M, Awada A, Selleslags J, Van Vreckem A, Van Glabbeke M: Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: Final results of a randomized study of the European Organization for research and treatment of cancer investigational drug branch for breast cancer. J Clin Oncol 15:3149-3155, 1997. (Pubitemid 27377507)